MITSUBISHI-HITACHI
19.5.2020 14:02:16 CEST | Business Wire | Press release
Mitsubishi Hitachi Power Systems (MHPS) ranks first in market share by megawatts for gas turbine orders in 2020 according to data obtained from McCoy Power Reports. First quarter global orders of 2,638 MW brought MHPS’ market share to 28.5 percent globally. This increase in gas turbine market share was largely responsible for worldwide order booking increasing 19.7 percent during MHPS’ fiscal year ending March 31, 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200519005485/en/
“The extremely competitive global gas turbine market has moved in our direction with a clear preference for our JAC gas turbines, which are more reliable than competitor’s gas turbines while providing record-setting fuel efficiency and output,” said Ken Kawai, MHPS President and Chief Executive Officer. “Sales of MHPS’ gas turbines in both the advanced class and aero-derivative segments have gained momentum as utilities, independent power producers and municipalities around the world seek to lower their electricity cost through our unique combination of proven reliability and world class performance.”
MHPS’ J-Series gas turbines first entered commercial operation in 2011 and hold world-record reliability at 99.5%. In addition, they deliver combined cycle efficiency greater than 64%. The installed fleet of J-Series gas turbines recently achieved one million hours of commercial operation worldwide, which is nearly double that of competitors’ similar sized gas turbines.
Boosting MHPS’ first quarter 2020 market share was an order for the first two renewable-hydrogen-capable JAC gas turbines for the Intermountain Power Agency in Delta, Utah. Dan Eldredge of the Intermountain Power Agency said, "We chose MHPS' JAC power trains because they offered the best overall solution for our power generation equipment requirements, including the fuel flexibility that will enable us to meet our incremental goals toward 100% carbon-free power generation by 2045. With MHPS' tools and support, we expect to reliably provide cleaner power for decades to come."
Forty-five J-Series gas turbines are in commercial operation, and total ordered capacity exceeds 25 GW globally. One hundred and four units have been technically selected in Brazil, Canada, Japan, Mexico, Peru, South Korea, Taiwan, Thailand, and the United States.
“The marketplace has recognized our efforts through a wave of technical selections and orders placed,” said Junichiro Masada, Senior Vice President, Co-Chief Technology Officer, and Deputy Head of Turbomachinery Headquarters, MHPS. “And we continue to improve our technology. For example, we recently synced to the grid in Takasago, Japan, and reached full load with the latest 60 Hz enhancement of the JAC, demonstrating record-setting output and combined cycle efficiency. Competitors are years away from entering operation with a gas turbine of this size or efficiency. In addition, we recently demonstrated a significant performance enhancement of the FT4000 at our test facility in West Palm Beach, Florida.”
The FT4000 aero-derivative gas turbine, with multiple active projects in North America and internationally, has tripled its global footprint in the past two years and captured significant market share in its class since the purchase of PW Power Systems (PWPS) in 2013. The PWPS FT4000 first entered commercial operation in 2015 and delivers industry-leading simple cycle efficiency, start time and ramp rate.
“We are proud that our technology has launched us to global leadership in the competitive gas turbine market,” said Ken Kawai, President and Chief Executive Officer. “We value the contributions of our employees around the world who are focused on bringing advanced technologies and energy solutions to the marketplace for affordable and reliable power supplies. We remain committed to enabling a decarbonized economy and helping to resolve the challenges facing our global society.”
About Mitsubishi Hitachi Power Systems, Ltd.
Mitsubishi Hitachi Power Systems, Ltd. (MHPS), headquartered in Yokohama, Japan, is a joint venture formed in February 2014 by Mitsubishi Heavy Industries, Ltd. and Hitachi, Ltd. integrating their operations in thermal power generation systems and other related businesses. MHPS recently announced that its name will soon change to Mitsubishi Power. MHPS today ranks among the world’s leading suppliers of equipment and services to the power generation market, backed by 100 billion yen in capital and approximately 20,000 employees worldwide. The Company’s products include GTCC (gas turbine combined-cycle) and IGCC (integrated coal gasification combined-cycle) power plants, gas/coal/oil-fired (steam) power plants, boilers, generators, gas and steam turbines, geothermal power plants, AQCS (air quality control systems), power plant peripheral equipment and solid-oxide fuel cells (SOFC). For more information, please visit the Company's website at https://www.mhps.com .
Follow us at
https://twitter.com/MHPS_Global
, or http://www.linkedin.com/showcase/mhps
View source version on businesswire.com: https://www.businesswire.com/news/home/20200519005485/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom